



The logo features the word "Cyclo" in a large, teal, sans-serif font. Each letter contains a different image: the 'C' shows a woman in a white dress with arms raised; the 'y' shows a young boy jumping; the 'c' shows a woman in a white top and red leggings in a yoga pose; the 'l' shows two children with colorful handprints; the 'o' shows an elderly couple embracing. To the right of "Cyclo" is a large teal vertical bar, followed by a blue 'o' containing a woman jumping. Below this is the word "therapeutics" in a blue, lowercase, sans-serif font.

Forward-Looking Statements

Some of the information in this presentation relates to future events or future business and financial performance. Such statements constitute forward-looking information within the meaning of the Private Securities Litigation Act of 1995. Such statements can be only predictions and the actual events or results may differ from those discussed due to, among other things, the risks described in the public filings and other publications of Cyclo Therapeutics, Inc. Forward-looking statements are identified by words such as “anticipates”, “projects”, “expects”, “plans”, “intends”, “believes”, “estimates”, “target”, and other similar expressions that indicate trends and future events.

The market data and certain other statistical information used throughout this presentation are based on independent industry publications, governmental publications, reports by market research firms or other independent sources. Some data are also based on the Company’s good faith estimates. In addition, this presentation includes summaries of scientific activities and outcomes that have been condensed to aid the reader in gaining general understanding.

The information about Cyclo Therapeutics, Inc. and its subsidiaries is solely for information purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any state.

Factors that could cause the Company’s results to differ materially from those expressed in forward looking statements include, without limitation, the Company’s need for additional capital; the Company’s reliance on its Trappsol® Cyclo™ product, which may never receive regulatory approval; the Company’s ability to commercialize any of its proposed drug products if it receives regulatory approval; the outcome of the Company’s clinical trials, which may not support the Company’s product claims or may result in adverse side effects; the cost and timing of the Company’s clinical trials; the Company’s reliance on third parties to conduct clinical trials and to produce its products; and other risks associated with being a clinical stage biotechnology company.

This presentation is not to be copied, transmitted, displayed, distributed (for compensation or otherwise), or altered in any way without the prior written consent of Cyclo Therapeutics, Inc.

Company Snapshot

Who: In 1990, the company was formed as Specialty Fine Chemical business specializing in cyclodextrins. In 2014, the business was expanded into a biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with challenging diseases.

What: Trappsol® Cyclo™ is a proprietary formulation of hydroxypropyl beta cyclodextrin and in multiple clinical studies has shown encouraging results to effectively manage the transportation of cholesterol.

Why: Because cholesterol is so important to the normal function of our cells, its synthesis and degradation is tightly controlled by an array of cellular processes. When there is an imbalance in cholesterol synthesis or metabolism, cells and organs may not function properly, leading to disease or death.

How: Trappsol® Cyclo™, with its cyclic structure, facilitates the transport of accumulated cholesterol out of cellular lysosomes so it can be further processed and excreted out of cells.

Currently Targeting 2 Serious Diseases with Unmet Medical Need

Niemann-Pick Disease Type C

Fatal and progressive genetic disorder
Orphan indication affecting >9,000 in 80 countries (~400 in U.S. / 320 EU5) ¹

Alzheimer's Disease

6th leading cause of death affecting 5 million people in the U.S.²


Platform technology has potential to fuel pipeline expansion opportunities

1. April 2021, Tessellon Inc. (former Kantar Health experts with 25+ years of epidemiology and forecasting experience), (www.Tessellon.com); Exhaustive literature search with a broad range of MESH terms in United States + 79 other countries.

2. <https://www.alz.org/alzheimers-dementia/facts-figures>

Platform Technology Pipeline:

Trappsol® Cyclo™ allows for a multiple shots on goal model



Ongoing Collaboration with University of the Witwatersrand, Johannesburg to Advance Trappsol® Cyclo™ Platform and Explore Pipeline Expansion Opportunities

Orphan Drug Designation in U.S. | Fast Track Status in U.S. | Potential for Priority Review Voucher (PRV) in U.S

Orphan Designation in EU | EMA Pediatric Investigational Plan Adopted

Leadership Team with Proven Experience



N. Scott Fine
Chief Executive Officer & Director



Joshua M. Fine
Chief Financial Officer



Lise Lund Kjems, MD, PhD
Chief Medical Officer



Michael Lisjak
Chief Regulatory Officer



Jeffrey L. Tate, Ph.D.
Chief Operating Officer, Chief Quality Officer & Director



Lori McKenna Gorski
Global Head of Patient Advocacy



Scientific Advisory Board



Rita Colwell, Ph.D.

Co-Chair

Internationally recognized scientist, microbiologist and founder of CosmosID, a privately held bioinformatics firm. Distinguished University Professor at U. Maryland and Johns Hopkins University. Former Director, National Science Foundation (1998 - 2006). National Medal of Science awardee. Member, US National Academy of Sciences.



Sharon H. Hrynkow, Ph.D.

Co-Chair

Neuroscientist with more than 25 years' experience in global health arena, public and private sectors. Senior executive at NIH. First president of non-profit Global Virus Network. Former Member of President's Council of Advisors on Science and Technology. 5 years at Cyclo Therapeutics leading clinical and scientific programs.



Benny Liu, M.D.

Key Opinion Leader in Niemann-Pick Disease Type C

Gastroenterologist at Alameda Healthy System, CA and Highland Hospital. Globally recognized expert in lipid metabolism. First to discover that cyclodextrins release cholesterol from cells using an animal model. Assistant Clinical Professor, UCSF.



Caroline Hastings, M.D.

Key Opinion Leader in Niemann-Pick Disease Type C

Pediatric hematologist oncologist, Director of NeuroOncology, and Professor of Pediatrics, UCSF Benioff Children's Hospital Oakland. First physician in US to use cyclodextrins for treatment in NPC, compassionate use. Advisor to US and Australian NPC Advocacy organizations and to physicians globally on NPC.



Gerald F. Cox, M.D., Ph.D.

Internationally Renowned for Clinical Drug Development

Seasoned biotechnology executive with 20-year successful track record of drug development for rare genetic diseases and extensive worldwide regulatory experience



Niemann-Pick Disease Type C

Ongoing Pivotal **TransportNPC™**
Phase 3 Study



NPC: A Debilitating Disease with Fatal Outcomes

- Rare, fatal and progressive genetic disorder affecting the brain, liver, spleen and lungs
- Characterized by a defect in the NPC1 protein
- Cholesterol and lipids accumulate in cells of major organs and tissues
- Leading to cell and tissue dysfunction

0 U.S. Approved NPC Therapies

1 EU Approved Therapy with No Systemic Effects

Market Opportunity¹

United States: \$300 Million | Worldwide: \$600 Million

Incidences

1/100,000 (~35 per year in U.S.)

Of Diagnosis

- ~ 3% are age 3 and below
- ~ 97% are age 3 and above
- ~ 60% age 16 and above

Median Survival

Early Infantile (2m-2): 4.6y

Late Infantile (3-6): 9.4y

Juvenile (7-15): 15.4y


Adolescent/Adult (16+): 12.2y

1: Data on file Cyclo Therapeutics

*Scope: United States + 79 other countries; *Commissioned Tessellon Inc – former Kantar Health experts with 25+ years of epidemiology and forecasting experience, (www.Tessellon.com); *Exhaustive literature search with a broad range of MESH terms.

Trappsol® Cyclo™

Enables the Effective Transport of Cholesterol Out of Cells



Cholesterol as measured by Filipin staining at Baseline and after 7 doses over 14 weeks



The lack of light blue represents the clearing of cholesterol from cells

Trappsol[®] Cyclo[™] Summary of Completed Clinical Studies in NPC

Study 101

Phase 1 study in NPC patients age 18 years and older showed Trappsol[®] Cyclo[™] was well-tolerated with an acceptable safety and tolerability profile

- After IV infusion, the drug is detectable in the cerebrospinal fluid within hours after the start of infusion
- Cholesterol synthesis and metabolism affected, and cholesterol cleared from cells, mimicking effects from nonclinical studies (*in vitro* and *in vivo*) in NPC models

Study 201

























Consistent pharmacodynamic effects and safety profile observed in a 48-week Phase 1/2 study in NPC patients aged 2 years and older

- 100% of patients assessed by treating physicians to be either stable or improved
- 88% (8 of 9 patients who completed the study), experienced clinically meaningful improvements in one or more efficacy endpoints, assessed by the 17 Domain NPC Severity Scale
- Based on totality of data from the Phase 1 and Phase 2 studies, the 2000 mg/kg dose was selected for the Phase 3 study

Double-blind, randomized, placebo-controlled, parallel-group study and is currently the most advanced clinical research program underway to identify a treatment for NPC

Number of Subjects	93
Current Sites	23 across 9 countries United States, United Kingdom, Italy, Germany, Spain, France, Poland, Israel, and Australia
Duration	96-week trial, with interim analysis at 48 weeks
Dose	2000 mg/kg via IV infusion
Primary Endpoint	NPC Composite Severity Score
Secondary Endpoints	SCAFI, Swallow, Vineland-2
Exploratory Endpoints	Inclusive of speech, liver and lung function

We Have the Only Active Late-Stage Clinical Program in NPC

Company	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Potential Indication (Systemic and Neurological)	Safety Profile	Summary
	Trappsol® Cyclo™ (Intravenous every 2 weeks, home infusions)							Met all primary endpoints of the Ph1 and Ph1/2 showing favorable safety and efficacy. Ph3 currently enrolling and additional site activation ongoing.
	Zavesca* (Oral 3 times daily)							FDA: Data did not support benefit risk. Off-label in US. EMA: Approved January 2009.
ORPHA 	Arimoclomol (Oral 3 times daily)							FDA: CRL received June 18, 2021, noting additional data required to support benefit risk. EMA: 23-Feb-2022, CHMP has notified of a negative trend vote following Oral Explanation. CHMP's current orientation is to not approve arimoclomol when it convenes by the end of March 2022.
	IB1001 (Oral 3 times daily)							Met with FDA, EMA and UK, Phase 3 study required, 6-month placebo-controlled crossover trial with approximately 50 patients (4 years of age and above). Study enrollment anticipated H1 2022.
	Adrabetadex (VTS-270) (Intrathecal every 2 weeks)							MNK concluded program 20-Jan-2021 noting the benefit risk is negative. Mandos received Court Approval to buy from MNK 29-Jun-2021. FDA has not found drug to be safe and effective for use to treat NPC1 or for any other use.
	ESB1609 (Oral, brain-penetrant)					TBD	TBD	Selective sphingosine-1-phosphate 5 (S1P5) receptor agonist.

Alzheimer's Disease

Open IND for
Phase 2 study



Alzheimer's Disease

The Most Common Form of Dementia

An irreversible, progressive neurologic disorder that slowly degrades memory, thinking and social skills that affects a person's ability to function independently.

Similarities with NPC

Cognitive decline

Elevated levels of tau

Amyloid plaques




- Affects more than 5 million people in the U.S.¹
- 6th leading cause of death in the U.S.¹
- 500,000 new cases every year²
- 13.8 million cases projected by 2050¹

Commonality Across Target Neurodegenerative Diseases


Alzheimer's Disease

Secondary Tauopathy



Niemann-Pick Disease Type C

Primary Tauopathy



Biologic Similarities

Cholesterol Accumulation in Regions of Brain

Elevated Levels of Tau in CSF

Amyloid Plaques in the Brain

Disease Manifestation

Cognitive decline / dementia

Premature death

Clumsiness

Progressive motor symptoms

Ataxia, dystonia, dysarthria, dysphasia

Psychiatric signs: psychosis, depression

Weight loss

Disease Manifestation

Progressive cognitive decline / early dementia

Premature death

Clumsiness, gait disturbance

Delayed motor milestones

Progressive: ataxia, dystonia

Seizures

Weight loss

Trappsol® Cyclo™ for the Potential Treatment of Alzheimer's Disease Targeting Reduction of Amyloid Beta and Tau

Received IND Clearance from the U.S. FDA to Advance Phase 2 Study

Preeminent Neuroscientist and World-Renowned Researcher,
Cynthia A. Lemere, PhD Senior Advisor for Advancement of Alzheimer's Disease Asset

Positive Results in Alzheimer Patient Under Compassionate Use Program

FDA authorized use of Trappsol® Cyclo™
in geriatric patient


18 months of monthly IV infusion

Disease did not progress

Family reported less volatility and greater word-
finding ability

18 months of data has led to development
of Phase 2 protocol

Alzheimer's Mini-Mental State Evaluation Performance¹



"The patient has shown cognitive and neurologic stability in serial examinations during this study that indicates possible benefit as there would be an expected measurable cognitive and functional decline over an 18-month period in persons with Alzheimer's disease dementia," Treating Physician

*Treating physician reported the 18-month score as a range between 24-26

1: Rate of MMSE decline in AD patients: Eldholm, RS et al, J. Alz. Disease, 61: 1221, 2018. Suh, GH et al., Intl. J. Geriatric Psychiatry, 19(9): 817, 2004.

Corporate Overview



Financial Snapshot - Nasdaq: CYTH

Cash
Balance¹

\$16.6

Market
Cap²

~\$22M

Shares
Outstanding

8.4M

Average
Volume²

~49K

Investment Summary

Leveraging over 3 decades of experience with cyclodextrins to advance clinically de-risked programs towards approval in diseases with unmet medical need

Platform technology has demonstrated to be safe and effective with over 10 years of patient exposure

TransportNPC™

Enrolling and dosing patients in Pivotal Phase 3 study in Niemann-Pick Disease Type C

Significant market opportunity with no approved therapy to treat both systemic and neurological manifestations of NPC

FDA: Orphan Drug Designation (ODD), Fast-Track, Rare Pediatric Disease Designation, potential PRV; EMA: ODD and adopted PIP

Pipeline expansion into Alzheimer's Disease (AD), patent filed globally and is currently being prosecuted

Received Study May Proceed from FDA December 2021, FPI targeted H2 2022



Multiple value-driving milestones expected

Platform technology with opportunity to expand into multiple indications

Leadership team with proven track-record in execution and value creation

NASDAQ: CYTH
cyclotherapeutics.com

cyclo
therapeutics

The logo for Cyclotherapeutics features the word "cyclo" in a large, teal, sans-serif font. The letter "o" is stylized as a teal ring with two dark blue circles attached to its outer edge. Below "cyclo" is the word "therapeutics" in a smaller, dark blue, sans-serif font.

Thank you!